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MaBACKGROUND It is unclear whether the non–vitamin K antagonist oral anticoagulant agents rivaroxaban and
dabigatran are superior to warfarin for efﬁcacy and safety outcomes in Asians with nonvalvular atrial ﬁbrillation
(NVAF).
OBJECTIVES The aim of this study was to compare the risk for thromboembolic events, bleeding, and mortality
associated with rivaroxaban and dabigatran versus warfarin in Asians with NVAF.
METHODS A nationwide retrospective cohort study was conducted of consecutive patients with NVAF taking rivarox-
aban (n ¼ 3,916), dabigatran (n ¼ 5,921), or warfarin (n ¼ 5,251) using data collected from the Taiwan National Health
Insurance Research Database between February 1, 2013 and December 31, 2013. The propensity score weighting method
was used to balance covariates across study groups. Patients were followed until the ﬁrst occurrence of any study
outcome or the study end date (December 31, 2013).
RESULTS A total of 3,425 (87%) and 5,301 (90%) patients were taking low-dose rivaroxaban (10 to 15 mg once daily)
and dabigatran (110 mg twice daily), respectively. Compared with warfarin, both rivaroxaban and dabigatran signiﬁcantly
decreased the risk for ischemic stroke or systemic embolism (p ¼ 0.0004 and p ¼ 0.0006, respectively), intracranial
hemorrhage (p ¼ 0.0007 and p ¼ 0.0005, respectively), and all-cause mortality (p < 0.0001 and p < 0.0001,
respectively) during the short follow-up period. In comparing the 2 non–vitamin K antagonist oral anticoagulant agents
with each other, no differences were found regarding risk for ischemic stroke or systemic embolism, intracranial hem-
orrhage, myocardial infarction, or mortality. Rivaroxaban carried a signiﬁcantly higher risk for hospitalization for
gastrointestinal bleeding than dabigatran (p ¼ 0.0416), but on-treatment analysis showed that the risk for hospitalized
gastrointestinal bleeding was similar between the 2 drugs (p ¼ 0.5783).
CONCLUSIONS In real-world practice among Asians with NVAF, both rivaroxaban and dabigatran were associated with
reduced risk for ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality without signif-
icantly increased risk for acute myocardial infarction or hospitalization for gastrointestinal bleeding compared with
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
AMI = acute myocardial
infarction
ASMD = absolute standardized
mean difference
CI = conﬁdence interval
CKD = chronic kidney disease
GI = gastrointestinal
HR = hazard ratio
ICH = intracranial hemorrhage
INR = international normalized
ratio
NHIRD = National Health
Insurance Research Database
NOAC = non–vitamin K
antagonist oral anticoagulant
agent
NVAF = nonvalvular atrial
ﬁbrillation
OAC = oral anticoagulant
agent
VKA = vitamin K antagonist
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1390A trial ﬁbrillation (AF) signiﬁcantly in-creases the risk for thromboembolicevents and death, affecting 2% to
3% of the global population (1,2). Oral antico-
agulants (OACs) such as vitamin K antago-
nists (VKAs) (such as warfarin) effectively
decrease the risk for thromboembolic events
in patients with AF, while increasing the
risk for intracranial hemorrhage (ICH) (3,4).
The results of several large trials have sug-
gested that non-VKA OACs (NOACs), such as
dabigatran, a direct thrombin inhibitor, and
rivaroxaban, a factor Xa inhibitor, are conve-
nient and safe alternatives to VKAs (5,6).
NOACs have been shown to be noninferior
or superior to VKAs in preventing thrombo-
embolic events, depending strongly on
choosing either standard-dose NOAC admin-
istration (i.e., 150 mg for dabigatran) or low-
dose NOAC administration (i.e., 110 mg for
dabigatran). Evaluation of NOAC safety has
shown that both dabigatran and rivaroxaban
reduced the risk for ICH, while unexpectedly
increasing the risk for gastrointestinal (GI)bleeding compared with warfarin (7,8).SEE PAGE 1402Of particular note, Asians show a higher risk for
ICH than non-Asians when taking VKAs (9), but
limited data are available to determine whether
NOACs are as effective and safe in an Asian popula-
tion than in non-Asians (10,11). In our recent study of
a large nationwide Asian cohort with nonvalvular AF
(NVAF) (12), dabigatran administered mainly at a low
dose of 110 mg twice daily was associated with
reduced risk for ischemic stroke, ICH, and all-cause
mortality compared with warfarin, and it did not in-
crease the risk for major GI bleeding compared with
warfarin. However, no published data are available to
directly compare efﬁcacy and safety outcomes in
Asians with AF who are taking rivaroxaban versus
dabigatran during the same period. The objective of
this study was to evaluate the risk for thromboem-
bolic events, bleeding events, and all-cause mortality
associated with the NOACs dabigatran and rivarox-
aban versus warfarin in a real-world population of
Asians with NVAF.
METHODS
In this retrospective cohort study, all patient data
were obtained from the Taiwan National Health In-
surance Research Database (NHIRD). Taiwan has a
mandatory universal health insurance programproviding comprehensive medical care coverage to all
Taiwanese, currently including >23 million enrollees.
The NHIRD is a national billing administrative data-
base of health care services covering >99% of the
Taiwanese population in 2014 (13). Because patients’
original NHIRD identiﬁcation numbers are encrypted
and deidentiﬁed to protect their privacy, informed
consent was waived. The consistent data encrypting
process made it feasible to link and continuously
follow all claims belonging to the same patient within
the NHIRD. The study protocol was approved by the
Institutional Review Board of Chang Gung Memorial
Hospital.
STUDY DESIGN. We studied patients with NVAF
treated with rivaroxaban, dabigatran, or warfarin
(Figure 1). We identiﬁed a total of 304,252 patients
with new AF using International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation code
427.31 from January 1, 1996, to December 31, 2013.
Among the 304,252 patients, 80,365 patients had at
least 1 prescription ﬁlled for rivaroxaban, dabigatran,
or warfarin after AF was diagnosed. The approval
dates of dabigatran and rivaroxaban in Taiwan
were June 1, 2012, and February 1, 2013, respectively.
We selected 3 study groups taking the ﬁrst dose
of rivaroxaban, dabigatran, or warfarin between
February 1, 2013 and December 31, 2013—rivaroxaban
(n ¼ 3,916), dabigatran (n ¼ 5,921), and warfarin
(n ¼ 5,251)—on the basis of each patient’s ﬁnal anti-
coagulant status. Some patients had experience with
more than 1 of the drugs studied. Thus, the detailed
proﬁle of each treatment group was as follows: 1) the
dabigatran group included only dabigatran users
(n ¼ 2,781), rivaroxaban-experienced dabigatran
users (n ¼ 45), and warfarin-experienced dabigatran
users (n ¼ 3,095); 2) the rivaroxaban group included
only rivaroxaban users (n ¼ 1,441), dabigatran-
experienced rivaroxaban users (n ¼ 375), and
warfarin-experienced rivaroxaban users (n ¼ 2,100);
and 3) the warfarin group included only warfarin
users (n ¼ 5,251). Dabigatran- or rivaroxaban-
experienced warfarin users (n ¼ 327) were excluded
from our analysis. The index date was deﬁned as the
date of ﬁrst prescription of these 2 NOACs or warfarin
after February 1, 2013, for each group. The follow-up
period was deﬁned as from the index date until the
ﬁrst occurrence of any study outcome or the end date
of the study period (December 31, 2013), whichever
came ﬁrst.
STUDY OUTCOMES. Six outcomes were used in the
present study to determine the efﬁcacy and safety of
NOACs and warfarin, including ischemic stroke or
systemic embolism, ICH, hospitalization for GI
FIGURE 1 Study Design
New AF patients from 1996-2013
(n=304,252)
Taking Rivaroxaban (R),
Dabigatran (D), or Warfarin (W)
after AF was diagnosed
(n=80,365)
Feb 1, 2013 to Dec. 31, 2013
Rivaroxaban users
(n=3,916)
Feb 1, 2013 to Dec. 31, 2013
Dabigatran users
(n=5,921)
Feb 1, 2013 to Dec. 31, 2013
Warfarin users
(n=5,251)
R 10mg QD
(n=416)
R 15mg QD
(n=3,009)
R 20mg QD
(n=491)
D 110mg BID
(n=5,301)
D 150mg BID
(n=620)
Exclusion if:
-      Patients were diagnosed with
        pulmonary embolism or deep
        vein thrombosis within 6
        months before AF was
        diagnosed (n=780)
-      Patients received joint
        replacement or valvular
        surgery within 6 months before
        AF was diagnosed (n=1,153)
-      Patients were diagnosed with
        end-stage renal disease
        (n=2,247)
-      Patients < 30 years of age
        (n=223)
-      R or D→W users (n=327)
-      Patients started R, D, or W
        before Feb 1, 2013 (n=60,547)
Followed until the first occurrence of any six study outcomes* or the end of the study period
(Dec. 31, 2013), whichever came first.
*Ischemic stroke/systemic embolism, acute myocardial infarction, intracranial hemorrhage,
hospitalized gastrointestinal bleeding, all hospitalized bleeding events, and all-cause mortality.
From a total of 304,252 patients with new atrial ﬁbrillation (AF), 3,916 rivaroxaban (R) users, 5,921 dabigatran (D) users, and 5,251 warfarin (W)
users were enrolled in this study. BID ¼ twice daily; QD ¼ once daily.
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1391bleeding, acute myocardial infarction (AMI), all hos-
pitalizations for bleeding, and all-cause mortality.
To avoid misclassiﬁcation, all study outcomes were
required to be discharge diagnoses. ICH was deﬁned
using the codes for atraumatic hemorrhage. Hospi-
talization for GI bleeding was deﬁned as ahospitalized primary code indicating bleeding in the
GI tract. All hospitalizations for bleeding events
included ICH, hospitalization for GI bleeding, and
other critical site bleeding. The International Classi-
ﬁcation of Diseases codes for the study outcomes
and other baseline covariates are summarized in
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1392Online Table 1. It must be noted that the same patient
could have more than 1 study outcome during the
study duration, but only the study outcome that
occurred ﬁrst was considered in the study.
Medical history and risk factors for thromboem-
bolic and bleeding events at baseline were refer-
enced to any claim record with the previous
diagnoses or medication codes prior to the index
date. A history of bleeding was conﬁned to events
within 6 months preceding the index date. A history
of speciﬁc prescribed medications was conﬁned to at
least once within 3 months preceding the index
date (12).
STATISTICAL ANALYSIS. The propensity score
method, which simulates the effect of a randomized
clinical trial for observational cohort data, was used
to study the effects of NOACs on the 6 study out-
comes (14). The propensity score is the predicted
probability of treatment conditional on selected
covariates using logistic regression. Hence, separate
propensity score modes were obtained for the
rivaroxaban-warfarin and dabigatran-warfarin com-
parisons. Inverse probability of treatment weights
of propensity scores was used to balance covariates
across the 3 study groups regarding time-to-event
analyses (incidence rate, log-rank test, and Cox
proportional hazards model). Incidence rates were
estimated using the total number of study out-
comes during the follow-up period divided by
person-years at risk. The risk for 6 study outcomes
for the 2 NOACs versus warfarin (reference) or
rivaroxaban versus dabigatran (reference) was
obtained using survival analysis (Kaplan-Meier
method and log-rank test for univariate analysis
and Cox proportional hazards regression for multi-
variate analysis). The balance of covariates at
baseline among study groups was assessed using
the absolute standardized mean difference (ASMD)
rather than statistical testing, because balance is a
property of the sample and not of an underlying
population. An ASMD #0.1 indicates a negligible
difference in potential confounders between the
2 study groups (14). Statistical signiﬁcance was
indicated by a p value < 0.05. All statistical ana-
lyses were performed using SAS version 9.4 (SAS
Institute, Cary, North Carolina).
RESULTS
We enrolled consecutive patients taking rivaroxaban
(n ¼ 3,916), dabigatran (n ¼ 5,921), or warfarin
(n¼ 5,251) from February 1, 2013, to December 31, 2013.
The mean adherence rates were 65  28%, 58  28%,and 63  31% for rivaroxaban, dabigatran, and
warfarin, respectively (p < 0.001 for analysis-of-
variance test). The number of dose alterations was
limited for either the rivaroxaban or dabigatran group
during the study period. For the dabigatran group, 179
patients (3.0%) had dose alterations: 100 were
switched from 150 to 110 mg and 79 were increased
from 110 to 150 mg. For the rivaroxaban group, 218
patients (5.6%) had dose alterations: 16 and 31 were
switched from 20 to 15 or 10 mg, respectively;
conversely, 16 and 66 patients were switched from 15
to either 20 or 10 mg, respectively; and, ﬁnally, 19 and
70 patients went from 10 to either 20 or 15 mg,
respectively.
Before propensity score weighting, both the rivar-
oxaban and dabigatran groups were older, had higher
CHA2DS2-VASc and HAS-BLED scores, and had a
higher proportion of comorbidities than the warfarin
group (Tables 1 and 2). After propensity score
weighting, the rivaroxaban and dabigatran groups
were well balanced in all characteristics (all
ASMDs <0.1). Both rivaroxaban and dabigatran were
associated with signiﬁcantly reduced risk for ischemic
stroke or systemic embolism, ICH, and all-cause
mortality compared with warfarin (all p values <
0.05 before and p < 0.001 after propensity score
weighting, respectively) (Table 3, Online Tables 2 and
3). No differences were found in hospitalized GI
bleeding or AMI for the 2 NOAC groups versus the
warfarin group. Kaplan-Meier curves showed early
separation of event-free curves for ischemic stroke or
systemic embolism, ICH, and all-cause mortality for
the 2 NOACs versus warfarin (Figures 2 and 3).
Because rivaroxaban and dabigatran groups had
similar baseline characteristics (all ASMDs <0.1),
propensity score weighting was not performed when
comparing the 2 NOACs with each other for the 6
outcomes. No differences were found in risk for
thromboembolic events, ICH, AMI, all hospitalized
bleeding, or all-cause mortality between rivaroxaban
and dabigatran (Table 3). However, rivaroxaban car-
ried a higher risk for hospitalization for GI bleeding
than dabigatran (hazard ratio [HR]: 1.60; 95% conﬁ-
dence interval [CI]: 1.11 to 2.51; p ¼ 0.0416). GI
bleeding events were further divided into critical and
noncritical bleeding, which was deﬁned as receiving
or not receiving blood transfusion. A signiﬁcantly
higher rate of noncritical bleeding was found in
rivaroxaban users than dabigatran users (1.99 vs. 1.04
events/100 patient-years; HR: 1.82; 95% CI: 1.06 to
3.12; p ¼ 0.0311). No signiﬁcant differences were
found in the critical bleeding rate associated with
rivaroxaban versus dabigatran use (0.69 vs. 0.58
TABLE 1 Baseline Characteristics of Patients Using Rivaroxaban Versus Warfarin
Propensity Score Weighting
Before After
Rivaroxaban
(n ¼ 3,916)
Warfarin
(n ¼ 5,251) ASMD
Rivaroxaban
(n ¼ 3,916)
Warfarin
(n ¼ 5,251) ASMD
Age, yrs 76  9 71  12 0.4551 76  9 76  8 0.0051
<65 11 32 11 11
65–74 29 26 29 28
75–84 43 30 43 43
$85 17 13 17 17
Female 46 44 0.0384 54 54 0.0039
CHA2DS2-VASc score* 4.12  1.62 3.33  1.82 0.4620 4.12  1.62 4.12  1.50 0.0015
HAS-BLED score† 3.11  1.14 2.69  1.33 0.3375 3.11  1.14 3.14  1.04 0.0275
Chronic kidney disease 22 21 0.0412 22 22 0.0096
Chronic liver disease 27 22 0.1206 27 27 0.0009
Congestive heart failure 16 16 0.0011 16 16 0.0009
Hypertension 87 75 0.2949 87 87 0.0015
Hyperlipidemia 51 42 0.1879 51 50 0.0160
Diabetes mellitus 41 36 0.0978 41 41 0.0069
Previous stroke 29 20 0.2298 29 29 0.0042
Previous TIA 5 2 0.1162 5 4 0.0074
Myocardial infarction 4 3 0.0218 4 4 0.0127
PAOD 0 0 0.0062 0 0 0.0018
History of bleeding 2 2 0.0244 2 3 0.0202
History of NSAIDs 23 26 0.0862 23 23 0.0181
History of antiplatelet agents 41 54 0.2647 41 44 0.0669
History of PPIs 7 7 0.0143 7 7 0.0171
History of steroids 4 6 0.0600 4 4 0.0095
PCI 9 6 0.0857 9 9 0.0044
CABG 1 1 0.0282 1 1 0.0021
Values are mean  SD or %. *CHA2DS2-VASc score awards 1 point each for congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65 to 74 years, and
female (sex category) and 2 points each for age $75 years and previous stroke or TIA. †HAS-BLED score awards 1 point each for hypertension, abnormal renal or liver function,
stroke, bleeding history, labile INR, age 65 years or older, and antiplatelet drug or alcohol use. (Labile INR could not be determined from claims and was excluded from this
scoring.)
ASMD ¼ absolute standardized mean difference; CABG ¼ coronary artery bypass graft; INR ¼ international normalized ratio; NSAID ¼ nonsteroidal anti-inﬂammatory drug;
PAOD ¼ peripheral arterial occlusive disease; PCI ¼ percutaneous coronary intervention; PPI ¼ proton pump inhibitor; TIA ¼ transient ischemic attack.
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1393events/100 patient-years; HR: 1.20; 95% CI: 0.52 to
2.75; p ¼ 0.6701) (Central Illustration). On-treatment
analysis was based on patients without any drug
interruption during the study period; the cohorts
included rivaroxaban (n ¼ 2,007), dabigatran (n ¼
2,387), or warfarin (n ¼ 2,526). On-treatment analysis
indicated that the risk for GI bleeding was similar
between rivaroxaban and dabigatran (HR: 1.16; 95%
CI: 0.68 to 1.99; p ¼ 0.5783). Both rivaroxaban and
dabigatran were associated with a lower risk for ICH
(p < 0.05 for both) and all-cause mortality (p < 0.005
for both) versus warfarin for the on-treatment anal-
ysis (Online Table 4).
Subgroup analysis was performed to determine
whether the NOACs had signiﬁcant protective
effects for 4 outcomes compared with warfarin.
A total of 3,425 (87%) and 5,301 (90%) patientswere taking low-dose rivaroxaban and dabigatran,
respectively. In contrast to low-dose NOACs, neither
standard-dose rivaroxaban (n ¼ 491) nor standard-
dose dabigatran (n ¼ 620) signiﬁcantly improved
safety and efﬁcacy outcomes compared with
warfarin (Online Figures 1 to 4). During the study
period, 1,441 (36.8%) and 2,475 (63.2%) patients
were OAC-naive and OAC-experienced rivaroxaban
users, respectively; 2,781 (47.0%) and 3,140 (53.0%)
patients were OAC-naive and OAC-experienced
dabigatran users, respectively. Subgroup analysis
was performed on the basis of age, presence of
chronic kidney disease (CKD), and CHA2DS2-VASc
and HAS-BLED scores. Rivaroxaban users with pre-
vious OAC experience or CKD showed signiﬁcantly
higher risk for GI bleeding than warfarin users
(Online Figure 3).
TABLE 2 Baseline Characteristics of Patients Using Dabigatran Versus Warfarin
Propensity Score Weighting
Before After
Dabigatran
(n ¼ 5,921)
Warfarin
(n ¼ 5,251) ASMD
Dabigatran
(n ¼ 5,921)
Warfarin
(n ¼ 5,251) ASMD
Age, yrs 75  9 71  12 0.4062 75  9 75  10 0.0214
<65 13 32 13 12
65–74 30 26 30 29
75–84 42 30 42 43
$85 16 13 16 16
Female 42 44 0.0375 42 42 0.0085
CHA2DS2-VASc score* 4.08  1.59 3.32  1.82 0.4412 4.08  1.59 4.12  1.87 0.0215
HAS-BLED score† 3.12  1.14 2.69  1.33 0.3440 3.12  1.14 3.19  1.30 0.0553
Chronic kidney disease 22 21 0.0402 22 22 0.0027
Chronic liver disease 28 22 0.1226 28 28 0.0005
Congestive heart failure 16 16 0.0070 16 16 0.0173
Hypertension 86 75 0.2774 86 86 0.0011
Hyperlipidemia 51 42 0.1898 51 51 0.0056
Diabetes mellitus 41 36 0.1084 41 41 0.0044
Previous stroke 32 20 0.2854 32 32 0.0059
Previous TIA 5 2 0.1387 5 5 0.0137
Myocardial infarction 3 3 0.0133 3 3 0.0063
PAOD 0 0 0.0187 0 0 0.0049
History of bleeding 2 2 0.0048 2 2 0.0171
History of NSAIDs 25 26 0.0257 25 26 0.0163
History of antiplatelet agents 45 54 0.1701 45 49 0.0845
History of PPIs 5 7 0.0820 5 6 0.0111
History of steroids 4 6 0.0546 4 5 0.0145
PCI 7 6 0.0237 7 7 0.0104
CABG 1 1 0.0424 1 1 0.0089
Values are mean  SD or %. *CHA2DS2-VASc score awards 1 point each for congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65 to 74 years, and
female (sex category) and 2 points each for age $75 years and previous stroke or TIA. †HAS-BLED score awards 1 point each for hypertension, abnormal renal or liver function,
stroke, bleeding history, labile INR, age 65 years or older, and antiplatelet drug or alcohol use. (Labile INR could not be determined from claims and was excluded from this
scoring.)
Abbreviations as in Table 1.
Chan et al. J A C C V O L . 6 8 , N O . 1 3 , 2 0 1 6
Rivaroxaban and Dabigatran in Asians With Atrial Fibrillation S E P T E M B E R 2 7 , 2 0 1 6 : 1 3 8 9 – 4 0 1
1394DISCUSSION
This was the ﬁrst population-based study to inves-
tigate the efﬁcacy and safety of rivaroxaban and
dabigatran with a speciﬁc focus on Asians with
NVAF taking these NOACs or warfarin during the
same period. No previous study had compared the
effects of these 2 NOACs directly in Asian patients.
The results of the present study showed that nearly
90% patients in this large Asian cohort with NVAF
were taking low-dose anticoagulant therapy (10 to
15 mg once daily for rivaroxaban or 110 mg twice
daily for dabigatran). Compared with warfarin, the
NOACs were associated with lower risk for ischemic
stroke or systemic embolism, ICH, and all-cause
mortality, without simultaneous increased risk for
AMI or hospitalization for GI bleeding. Of note, no
differences were found between rivaroxaban anddabigatran in risk for thromboembolic events, ICH,
critical GI bleeding, or all-cause mortality. However,
rivaroxaban was associated with a higher risk for
noncritical GI bleeding than dabigatran in the Asian
cohort. Subgroup analysis indicated that rivarox-
aban users with previous OAC experience or CKD
showed a particularly increased risk for GI bleeding
compared with such patients taking warfarin.
The risk for GI bleeding was similar between dabi-
gatran and rivaroxaban for the on-treatment
analysis.
Our results indicated that physicians tend to
prescribe low-dose NOACs to their Asian patients
with AF. Several reasons may explain why physi-
cians in Taiwan favor low-dose NOACs. First, the
average lower body mass index of adults in Taiwan
is approximately 23 kg/m2, which is much lower than
the mean value (w28 kg/m2) for patients enrolled in
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1395the RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) and ROCKET AF (Rivarox-
aban Once Daily Oral Direct Factor Xa Inhibition
Compared With Vitamin K Antagonism for Preven-
tion of Stroke and Embolism Trial in Atrial Fibrilla-
tion) trials (5,6,12). Therefore, given the lower body
size, physicians tend to prescribe low-dose NOACs
for their Asian patients. Second, although Taiwanese
and Korean stroke guidelines recommend a target
international normalized ratio (INR) of 2.0 to 3.0 in
patients with AF taking warfarin, the Japanese and
Chinese AF guidelines suggest a lower INR of 1.6 to
2.5 for older adult patients with AF (age >70 years)
or those with high bleeding risk (15). Accordingly,
some physicians may prescribe lower-dose NOACs to
mimic the reduced INR of warfarin. Third, NOACs
are restricted to older patients (age $65 years) with
multiple comorbidities by the Taiwan national in-
surance system because of ﬁnancial considerations,
potentially selecting older patients and those with
multiple comorbidities compared with warfarin
users (Table 1). Physicians appear to be relatively
cautious about prescribing standard-dose NOACs for
older patients with AF with high CHA2DS2-VASc and
HAS-BLED scores. Finally, Asian patients are partic-
ularly exposed to higher risk for VKA-related ICH
than other ethnic groups (9). As a result of this
concern, NOACs may be also underdosed in Asian
patients.
Although the superior safety of low-dose NOACs
versus VKAs has been well documented, the efﬁcacy
of low-dose NOACs over VKAs remained question-
able until now. The RE-LY trial indicated that
dabigatran 110 mg was not different from warfarin
for reducing thromboembolic events (5). The
ENGAGE-AF (Effective Anticoagulation With Factor
Xa Next Generation in Atrial Fibrillation) trial
showed that edoxaban 30 mg was associated with
an unfavorable trend in reducing the risk for
ischemic stroke or systemic embolism compared
with warfarin (HR: 1.13; p ¼ 0.10) (16). The J-
ROCKET AF (Japanese ROCKET AF) study showed a
trend (p ¼ 0.05) toward improved efﬁcacy for low-
dose rivaroxaban (15 or 10 mg once daily) (17).
Correspondingly, a meta-analysis including those
trials concluded that low-dose NOACs are similarly
effective as VKAs in stroke or systemic embolism
prevention for both Asian and non-Asian patients
but might not be as effective for protection against
ischemic stroke (11). The numbers of Asian patients
taking low-dose NOACs in those studies were actu-
ally very limited.
In contrast, the present study was the largest ever
to examine the efﬁcacy of low-dose NOACs in Asians,
FIGURE 2 Outcomes: Rivaroxaban Versus Warfarin
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Rivaroxaban (R) users had a signiﬁcantly lower risk for ischemic stroke or systemic embolism (A), intracranial hemorrhage (B), and all-cause
mortality (F), without increased risk for acute myocardial infarction (C), hospitalized gastrointestinal bleeding (D), or any hospitalized bleeding
(E) compared with warfarin (W) users.
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1396enrolling a total of 3,425 patients taking low-dose
rivaroxaban and 5,301 patients taking low-dose
dabigatran; low-dose treatment with either NOAC
signiﬁcantly decreased the risk for ischemic stroke orsystemic embolism and all-cause mortality compared
with warfarin during the short follow-up period. In
general, Asians are smaller in body size and body
mass index compared with non-Asians (12).
FIGURE 3 Outcomes: Dabigatran Versus Warfarin
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Dabigatran (D) users had a signiﬁcantly lower risk for ischemic stroke or systemic embolism (A), intracranial hemorrhage (B), hospitalization for
any bleeding (E), and all-cause mortality (F) and a similar risk for acute myocardial infarction (C) and hospitalization for gastrointestinal
bleeding (D) compared with warfarin (W) users.
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1397Therefore, low-dose NOACs may be potent enough at
reducing thromboembolic events in Asians with low
body mass. Another issue is the inadequate time in
the therapeutic range of warfarin, which is commonlyseen in Taiwan as well as in other Asian countries
(18,19). Moreover, warfarin has been known to
interact with several herbal drugs and beverages,
including dong quai, ginseng, ginger, garlic, ginkgo,
CENTRAL ILLUSTRATION Hospitalization for Gastrointestinal Bleeding With Non–Vitamin K Antagonist
Oral Anticoagulant Agents
Chan, Y.-H. et al. J Am Coll Cardiol. 2016;68(13):1389–401.
Compared with each other, rivaroxaban carried a signiﬁcantly higher risk for hospitalization for gastrointestinal bleeding (A), driven by signiﬁcant
differences in noncritical (C) rather than critical (B) bleeding.
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1398and green tea, which are commonly used in Asian
countries (20). The frequent drug-drug interactions
may interfere with the stability of INR maintenance in
Asians. Furthermore, most physicians in Asia
implicitly target the low end of the target range of INR
for their patients taking VKAs because of particular
concern about the higher risk for ICH seen among
Asians compared with non-Asian patients, even when
INR is ideally maintained (9,18). Chan et al. (21)
recently reported that low-dose dabigatran was
associated with a superior reduction in stroke risk and
ICH compared with warfarin, which was associated
with a time in the therapeutic range $55% in older
Chinese patients with AF. Those investigatorsspeculated that higher plasma concentration of
dabigatran caused by advanced age and reduced
creatinine clearance may explain the superior per-
formance of low-dose dabigatran in their patients.
This rationale also may help explain ﬁndings of the
present study, because the indications for NOACs are
restricted to older Taiwanese (age $65 years), and
Taiwanese have been noted to have a high prevalence
of CKD (22); we showed higher bleeding with warfarin
in patients with CKD in this study. The J-ROCKET AF
trial also indicated that the pharmacokinetic proﬁle of
a 15-mg dose of rivaroxaban in Japanese patients was
similar to that of a 20-mg dose in Caucasian patients
(17) and further conﬁrmed that low-dose rivaroxaban
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1399signiﬁcantly reduced the risk for ischemic stroke.
Further study is warranted to deﬁne the optimal dose
of NOACs in older Asians with AF.
The present study speciﬁcally focused on “short-
term” outcomes because of 2014 NHIRD data unre-
leased until now, meaning that the duration of all
patients taking OACs was <1 year (February 1 to
December 31, 2013). Notably, early thromboembolic
and bleeding events can have a major impact on the
overall success of treatment in patients with AF,
which is closely related to the persistence of long-
term treatment (23). However, the results of the
present study differed from those of a recent obser-
vational study using a French medical-administrative
database that found no signiﬁcant differences in
bleeding or thromboembolic risk for dabigatran or
rivaroxaban versus VKA during the early phase of
treatment (24). In contrast, our analyses indicated
that low-dose NOACs can be safer and more effective
alternatives to warfarin, speciﬁcally in Asians during
the early phase of treatment. However, we unex-
pectedly found that rivaroxaban carried a higher risk
for hospitalization for GI bleeding than dabigatran in
this large Asian cohort. Recently, results of a large
real-world study presented by Tepper et al. (25)
indicated that rivaroxaban users (n ¼ 30,529)
appear to have higher risk for major GI bleeding than
dabigatran (n ¼ 20,963) and apixaban (n ¼ 8,785)
users in the ﬁrst 6 months after treatment initiation.
Although the data source of Tepper et al. was from
patients with non-Asian ethnicity, our study popu-
lation was still similar to their cohort, as both study
cohorts comprised new NOAC initiators and/or
switchers from warfarin; plus, both studies focused
speciﬁcally on short-term outcomes after NOAC
initiation. The age distribution and other baseline
characteristics of the cohort in the present study
were similar between dabigatran and rivaroxaban
groups (Tables 1 and 2). The increased risk for GI
bleeding in the rivaroxaban group may be explained
by several unmeasured confounders, including poor
compliance or unmeasured serious comorbidities.
One possible explanation is that the rivaroxaban
group comprised a higher proportion of switchers
from another OAC (w63%) than the dabigatran group
(w53%). The ROCKET AF subgroup analysis indicated
that VKA-experienced patients have a signiﬁcantly
higher risk for major bleeding than VKA-naive pa-
tients (26). In contrast, the RE-LY trial revealed that
both VKA-experienced and VKA-naive dabigatran
users had similar safety outcomes compared with
warfarin (27). Like the subgroup analyses of the RE-
LY and ROCKET AF trials, the present study
revealed that OAC-experienced rivaroxaban userscarried a signiﬁcantly higher risk for GI bleeding than
OAC-naive rivaroxaban users, while the risk for GI
bleeding was similar between OAC-experienced and
OAC-naive dabigatran users compared with warfarin
(Online Figure 3). Further studies enrolling larger
cohorts of Asian subjects are necessary to conﬁrm
our ﬁndings for risk for GI bleeding between dabi-
gatran and rivaroxaban during the early phase of
treatment.
STUDY LIMITATIONS. First, renal excretion rates of
rivaroxaban and dabigatran are largely different, and
the choice of the low dose of NOACs may be guided
according to the measurements of serum renal
function for each patient. However, the NHIRD does
not contain laboratory data, so important informa-
tion was not available for analysis, including serum
hemoglobin, renal and liver function, and INR.
Because the coding of CKD depends entirely on each
physician’s choice in clinical practice, the population
of patients with CKD may have been heteroge-
neously contaminated in our study. Also, although a
number of variables were selected in our propensity
score model, and a close balance of those factors
was achieved, residual confounding by unmeasured
factors cannot be excluded. Coding errors of out-
comes and comorbidities registered by each physi-
cian constitute a limitation of Taiwan’s NHIRD.
However, only primary discharge diagnoses were
used, to improve the outcome accuracy of the pre-
sent study. Furthermore, the reliability of the AF
database for the NHIRD and the diagnostic accu-
racies of those factors have been validated previ-
ously (28–31).
Another potential limitation was the adherence
rate of anticoagulant agents in our study, which was
calculated on the basis of the prescription period
divided by the total follow-up period. The actual
adherence rate may have been lower than the pre-
scription rate obtained in the study. Additionally, we
did not classify the patient group on the basis of
initial anticoagulant regimen, because of the
complexity of anticoagulant switching during the
treatment course. If patients are grouped on the
basis of their initial regimens, it may be hard to
conclusively attribute risk for a speciﬁc clinical
event to a particular anticoagulant regimen or
possible switching/bridging gaps between different
regimens during follow-up. Instead, we classiﬁed
each patient on the basis of his or her ﬁnal antico-
agulant regimen and followed from “ﬁrst prescrip-
tion of ﬁnal anticoagulant (the index date)” until the
study end date or the occurrence of an event, which
might have reduced the contamination of other
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Limited data indicated that NOACs may be more
effective and safer in Asians than in non-Asians. This
was the ﬁrst population-based study to investigate
efﬁcacy and safety with a speciﬁc focus on Asians with
NVAF taking rivaroxaban, dabigatran, or warfarin
during the same period.
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Low-dose rivaroxaban and
dabigatran were associated with a reduced risk for
ischemic stroke or systemic embolism, ICH, and all-
cause mortality without increasing risk for AMI or
hospitalized GI bleeding compared with warfarin in a
national Asian cohort during the early phase of
treatment. Although rivaroxaban carried a higher risk
for hospitalization for GI bleeding than dabigatran for
the intention-to-treat analysis, that risk was similar in
the on-treatment analysis.
TRANSLATIONAL OUTLOOK 1: Although this was
a relatively short-term study, long-term follow-up of
Asians taking NOACs will lead to better understanding
of the comparative beneﬁts conveyed by these 2
NOACs versus warfarin.
TRANSLATIONAL OUTLOOK 2: Further study
enrolling more Asian subjects is necessary to conﬁrm
ﬁndings of the present study regarding different
levels of risk for hospitalization for GI bleeding be-
tween rivaroxaban and dabigatran.
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1400anticoagulant agents. However, the possibility of
misclassiﬁcation for patient groups could not be
avoided.
Finally, the follow-up period of NOAC administra-
tion in our study was short because of 2014 NHIRD
data unreleased. Although signiﬁcant divergence ex-
ists for thromboembolic events, ICH, and all-cause
mortality between NOACs and warfarin during the
early phase of treatment, it is unclear whether the
efﬁcacy and safety of NOACs persist after long-term
follow-up. Also, other NOACs, such as apixaban and
edoxaban, were not included because they were
approved after 2014 in Taiwan.
CONCLUSIONS
Low-dose rivaroxaban and dabigatran were associ-
ated with reduced risk for ischemic stroke or sys-
temic embolism, ICH, and all cause-mortality
compared with warfarin in a large Asian cohort. The
2 NOACs were not associated with signiﬁcantly
higher risk for hospitalization for GI bleeding or AMI
than warfarin. Although rivaroxaban carried a higher
risk for GI bleeding than dabigatran in this large
Asian cohort for the intention-to-treat analysis, in
the on-treatment analysis, the risk for GI bleeding
was similar between these NOACs. Either rivarox-
aban or dabigatran may be a safer and more effec-
tive alternative to warfarin in Asian patients with
NVAF.
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